Retrospective study of the associations between hepatitis C virus infection and metabolic factors

Shira Yair-Sabag, Elchanan Nussinson, Ofir Ben-Assuli, Fahmi Shibli, Azmi Shahbari, Shira Zelber-Sagi

Shira Yair-Sabag, Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, gastroenterology Institute, Emek Medical Center, Afula 18742, Israel
Shira Yair-Sabag, Shira Zelber-Sagi, School of Public Health, University of Haifa, Haifa 3498838, Israel
Ofir Ben-Assuli, Ono Academic College, Kiryat Ono 5545173, Israel

Author contributions: Yair-Sabag S performed the research and drafted and wrote the paper; Yair-Sabag S, Nussinson E and Zelber-Sagi S contributed equally to this manuscript; Nussinson E wrote the paper and supervised the study; Ben-Assuli O provided analytical oversight; Shibli F and Shahbari A provided administrative support; Zelber-Sagi S designed and supervised the study.

Institutional review board statement: This study was reviewed and approved by the Haifa University and Emek Medical Center Institutional Review Boards.

Informed consent statement: All study participants provided verbal informed consent prior to study enrollment.

Conflict-of-interest statement: There are no conflicts of interest to declare.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Elchanan Nussinson, MD, Gastro-enterology Institute, Emek Medical Center, Duchifat 7 St, Afula 18742, Israel. elchananm@gmail.com Telephone: +972-54-4943922 Fax: +972-4-6523745

Received: May 8, 2016 Peer-review started: May 9, 2016 First decision: June 13, 2016 Revised: July 28, 2016 Accepted: September 13, 2016 Article in press: September 18, 2016 Published online: October 28, 2016

Abstract

AIM
To evaluate the bidirectional association between metabolic syndrome (MS) components and antiviral treatment response for chronic hepatitis C virus (HCV) infection.

METHODS
This retrospective cohort study included 119 HCV + patients treated with pegylated-interferon-α and ribavirin. Metabolic characteristics and laboratory data were collected from medical records. Differences in baseline clinical and demographic risk factors between responders and non-responders were assessed using independent samples t-tests or χ² tests. The effects of sustained viral response (SVR) to antiviral treatment on de novo impairments in MS components, including impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM), were assessed using univariable and multivariable logistic regression analysis, while the effect of MS components on SVR was assessed using univariable logistic regression analysis.

RESULTS
Of the 119 patients, 80 (67%) developed SVR over the
average 54 ± 13 mo follow-up. The cumulative risks for 
de novo T2DM and IFG were 5.07- (95%CI: 1.261-20.4, 
P = 0.022) and 3.87-fold higher (95%CI: 1.484-10.15, 
P = 0.006), respectively for non-responders than 
responders, when adjusted for the baseline risk factors 
age, sex, HCV genotype, high viral load, and steatosis. 
Post-treatment triglyceride levels were significantly lower 
in non-responders than in responders (OR = 0.27; 
95%CI: 0.069-0.962, P = 0.044). Age and HCV genotype 
3 were significantly different between responders and 
non-responders, and MS components were not 
significantly associated with SVR. Steatosis tended to 
attenuate SVR (OR = 0.596; 95%CI: 0.331-1.073, P = 
0.08).

CONCLUSION
SVR was associated with lower de novo T2DM and 
IFG incidence and higher triglyceride levels. Patients 
infected with HCV should undergo T2DM screening and 
antidiabetic treatment.

Key words: Hepatitis C virus; Type 2 diabetes mellitus; 
Antiviral therapy; Sustained viral response; Metabolic 
syndrome; Hepatic steatosis; Peg interferon alpha; Ribavirin; Direct acting antiviral agents

Core tip: Hepatitis C virus (HCV) is associated with a 
unique metabolic syndrome (MS) type: Insulin resistance 
with type 2 diabetes mellitus (T2DM), hypercho-

lesterolemia, and liver steatosis. We retrospectively 
investigated the association between MS components 
and HCV infection, including antiviral therapy response, 
for 119 patients infected with HCV treated with inter-
feron alpha and ribavirin. After long-term follow-up, 
de novo T2DM incidence significantly decreased, and 
triglyceride levels significantly increased in treatment 
responders. Only steatosis tended to affect treatment 
response. The association between HCV and lipid 
metabolic pathways may be important even with new 
direct antiviral agents. Patients infected with HCV should be screened for T2DM.

Yair-Sabag S, Nussinson E, Ben-Assuli O, Shibli F, Shahbari A, 
Zelber-Sagi S. Retrospective study of the associations between 
hepatitis C virus infection and metabolic factors. World J Hepatol 
2016; 8(30): 1269-1278 Available from: URL: http://www. 
wjgonet.com/1948-5182/full/v8/i30/1269.htm DOI: http://dx.doi. 
org/10.4254/wjh.v8.i30.1269

INTRODUCTION
A mutual association between hepatitis C virus (HCV) 
infection and host metabolism has been demonstrated in several studies. HCV depends on host lipids for entry 
into the hepatocytes and for its replication; in return, 
HCV also affects the metabolism of host lipids\[1-3\].

HCV causes insulin resistance, hepatic steatosis, type 2 diabetes mellitus (T2DM), and low serum cho-

lesterol and triglyceride (TG) levels. Insulin resistance 
contributes to HCV-related disruption of glucose and 
lipid metabolism\[4\], and it is a key factor in metabolic 
syndrome (MS). In addition, HCV infection might lead to 
hepatic steatosis via several pathways.

Hepatic steatosis might aggravate MS directly by 
causing further insulin resistance\[5\] or indirectly because 
of resultant hepatic fibrosis\[6\] or cirrhosis\[7,8\]. After HCV 
infection, cholesterol and TG levels decrease, creating 
a different lipid profile from that for MS\[9\]. However, 
T2DM might be twice as prevalent in patients infected 
with HCV compared to the general population\[5\]. HCV 
has been associated with a unique type of MS called 
hepatitis C-associated dysmetabolic syndrome (HCADS), 
which includes liver steatosis, insulin resistance, and 
hypcholesterolemia\[5,10\]. Reversal of hypcholesterolemia 
and steatosis after achieving sustained viral response 
(SVR) with antiviral therapy has been observed in several studies\[11-13\].

Therefore, although MS is not clearly associated 
with HCV, there is an association between HCV and 
some MS components. HCV-induced fatty liver and 
inulin resistance leads to T2DM; with the additional 
presence of MS, HCV replication is accelerated by 
activation of hepatocyte transcription factors, leading 
to increased lipogenesis and the provision of lipids for 
HCV replication\[5,9,10\]. Furthermore, in patients with MS, 
immune responses to HCV can be attenuated by leptin 
resistance or other changes in adipokine secretion\[5\]. 
Thus, MS might interfere with SVR after treatment\[11,14-17\].

Previous studies showed that HCV eradication de-
creases the risk of de novo glucose abnormalities and 
inulin resistance. On the other hand, some studies 
reported neither an association between metabolic 
syndrome and HCV infection\[18\] nor reduced incidence of 
de novo glucose abnormalities in responders to treat-
ment with interferon alpha and ribavirin\[19\].

Our study aimed to assess the association between 
MS components and HCV infection based on the re-
sponse to the therapy as well as to evaluate the influence 
of MS components on the response to antiviral therapy in 
a younger cohort of HCV-infected patients with a long 
term follow-up.

MATERIALS AND METHODS
During 2004-2008, 119 patients diagnosed with chronic 
HCV infection, based on positive HCV RNA findings on 
polymerase chain reaction (PCR), were treated with 
combination pegylated-interferon α (Peg-IFNα) and 
ribavirin in the department of gastroenterology at Emek 
Medical Center in Afula, Israel. All patients were eligible 
for the Peg-IFNα and ribavirin treatment, which consisted of 
180 µg Peg-IFNα administered subcutaneously once 
a week and 800-1200 mg ribavirin administered orally
daily. Treatment lasted 24 wk for patients with genotypes 2/3 and 48 wk for those with genotypes 1/4.

Patients with hepatocellular carcinoma (HCC), human immunodeficiency virus infection, other serious conditions, or evidence of drug abuse or excessive alcohol consumption during the year preceding the enrollment were excluded.

**Metabolic and demographic characteristics**

Patients were evaluated before treatment, 6 mo after treatment, and every year after the end of treatment until 2011. Age, body mass index (BMI), serum fasting blood glucose, TG, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, aspartate transaminase, alanine transaminase, viral load, blood pressure, liver biopsy results, and liver ultrasonography were obtained from medical records and were not available in some cases. To reduce data bias, all data were extracted from several independent sources, including patient hospital files, electronic files from the family physician, and laboratory results every year after the end of treatment. The study was performed after obtaining local ethics committee approval.

Impaired fasting glucose (IFG) was defined as a serum fasting glucose level > 100 mg/dL, and T2DM was identified based on diagnoses documented in medical records, serum fasting glucose level > 126 mg/dL, or use of antidiabetic drugs. MS was defined using the World Health Organization clinical criteria for MS. Serum anti-HCV antibodies were measured using a 2nd generation immunoassay, and HCV RNA was measured using real time-PCR (RT-PCR; Amplicor HCV test, Roche Diagnostic; detection rate = 50 IU/mL). HCV genotyping was determined using RT-PCR (HCV genotyping, DNA immunoassay).

Most, but not all, patients agreed to and underwent a baseline liver biopsy to determine hepatic inflammation and steatosis. In addition, ultrasonography was performed before treatment and during the follow-up period to determine hepatic steatosis.

**Statistical analysis**

The statistical methods of this study were reviewed by Shira Zelber-Sagi from the School of Public Health at the University of Haifa and Ofir Ben-Assuli from Ono Academic College.

Continuous variables (MS components) are presented as means ± SD. Statistical analyses were performed using SPSS version 21 (IBM Corp., Armonk, NY, United States), and $P < 0.05$ was considered statistically significant for all analyses.

The response to treatment was the independent variable, and metabolic components were initially evaluated separately as dependent variables using independent samples $t$-tests or Mann-Whitney U tests, when appropriate, for continuous variables (e.g., age and BMI) and Pearson's $\chi^2$ tests and odds ratios (ORs) for categorical variables (e.g., sex and genotype).

To test differences from baseline to the average follow-up duration in continuous variables between the treatment responders and non-responders, independent samples $t$-tests were performed.

The difference in de novo occurrence of MS components ($0 = $ normal values; $1 = $ abnormal values indicating presence of the component) between responders and non-responders was calculated after excluding patients with MS components prior to antiviral treatment. Then, logistic regression analysis of de novo occurrence of T2DM and other MS components was conducted at different time intervals using an unadjusted (univariable) logistic regression (model 1) and an adjusted (multivariable) logistic regression (model 2, adjusted for age, sex, BMI, and genotype). Additionally, the cumulative rates of the patients without de novo occurrence of IFG, T2DM, and MS were estimated using the Kaplan-Meier method and compared between responders and non-responders using the log-rank test.

The effects of metabolic, demographic, and clinical variables on treatment response were determined using univariable logistic regression analysis.

**RESULTS**

The mean age of the 119 HCV-positive patients treated with Peg-IFN$\alpha$ and ribavirin (57% men, 43% women) was 41 ± 11.3 years (Table 1). The sample population primarily included immigrants from the Union of Soviet Socialist Republics (77%). The proportions of patients with HCV genotypes 1, 2, 3 and 4 were 66%, 9.2%, 22% and 1.7%, respectively (Table 1). The mean follow-up duration for MS components after treatment was 47.5 ± 13.3 mo.

Regarding MS components, hypertension, T2DM, and IFG were present in 17%, 9.2%, and 27.7% of patients, respectively (Table 1). Serum HDL values were within the lower limit of the normal range, and serum TG levels were within the normal range. Mean BMI was in the overweight range ($27 \pm 5.4$ kg/m$^2$). Steatosis was present in 36% or 16.5% of patients, as determined with liver biopsy or abdominal ultrasound, respectively (Table 1).

SVR was obtained in 67% ($n = 80$) of patients. Only baseline age and HCV genotype 3 were significantly different between responders and non-responders (Table 2). Non-responders were significantly older ($P = 0.017$), and significantly fewer non-responders had HCV genotype 3 ($P = 0.005$).

In the unadjusted regression analysis of the effect of the baseline metabolic factors on treatment response, metabolic syndrome and metabolic components (except T2DM) negatively affected treatment response (OR = 0.448; OR = 0.597; respectively), though none of them were significantly associated with treatment response ($P = 0.847$ and $P = 0.483$; respectively) (Table 3).
In the unadjusted regression analysis of the effect of the baseline demographic and clinical variables on treatment response, the ORs for HCV genotype 3 and age were significant (OR = 5.35; 95%CI: 1.48-19.3; *P* = 0.01 and OR = 0.959; 95%CI: 0.926-9.93; *P* = 0.019; respectively), suggesting positive effects of genotype 3 and relatively young age on response to treatment (Table 4). While the rate of hepatic steatosis as determined using abdominal ultrasound (16.5%) was not significant, the rate of hepatic steatosis as determined by liver biopsy (64%) tended to result in a better response (*P* = 0.085) (Table 4).

### Table 1 Baseline characteristics of the hepatitis C virus-infected patients treated with pegylated-interferon α and ribavirin

| Variable (normal values) | n¹ |
|---------------------------|----|
| Age (yr)                  | 119| 41 ± 11.3 |
| Sex (men %)               | 57.1| |
| Birth place (%)           | 12.6| |
| Israel                    | 77.3| |
| Union of Soviet Socialist Republics | 10 |
| Other (Europe, North America, South Africa, Georgia) | |
| Vinal load (IU/mL)        | 114| 461.234 ± 251.445 |
| HCV genotype (%)          |     | |
| 1                         | 66.4| |
| 2                         | 9.2 | |
| 3                         | 22.7| |
| 4                         | 1.7 | |
| BMI (19-25 kg/m²)         | 81 | 27.0 ± 5.4 |
| Systolic BP (15.99 kPa)   | 108| 15.59 ± 2.26 |
| Diastolic BP (10.66 kPa)  | 108| 9.06 ± 1.56 |
| Serum glucose (70-100 mg/dL) | 98 | 96.96 ± 20.5 |
| Cholesterol (100-200 mg/dL) | 117 | 176 ± 49 |
| Triglycerides (30-150 mg/dL) | 90 | 116 ± 65 |
| HDL (40-60 mg/dL)         | 74 | 48.8 ± 12 |
| AST (3-32 IU)             | 119| 51 ± 32 |
| ALT (5-33 IU)             | 119| 77 ± 59 |
| T2DM (diagnosis, fasting blood glucose > 126 mg/dL, or use of anti-diabetic drugs) (%) | 2.7 | |
| IFG or T2DM (fasting blood glucose > 100 mg/dL) (%) | 27.7 | |
| Steatosis determined using liver biopsy (n = 85)¹ | |
| Without steatosis (%)     | 36 | |
| Mild                      | 37.3| |
| Moderate                  | 25.3| |
| Severe                    | 1.3 | |
| Steatosis determined using abdominal ultrasound (n = 110; with steatosis) (%) | 16.5 | |

Values are reported as mean ± SD or %. ¹Data were not available for some patients due to the retrospective nature of the study; ²Some of the patients refused to undergo liver biopsy. HCV: Hepatitis C virus; BMI: Body mass index; BP: Blood pressure; HDL: High-density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; T2DM: Type 2 diabetes mellitus; IFG: Impaired fasting glucose.

### Table 2 Comparison of baseline characteristics between responders and non-responders to treatment with pegylated-interferon α and ribavirin

| Variable | Non-responders | Responders | *P* value¹ |
|----------|----------------|------------|------------|
| Age (yr) | 44.62 ± 11.22  | 39.42 ± 11.14 | 0.017      |
| BMI (kg/m²) | 26.88 ± 5.11  | 27.34 ± 5.70  | 0.717      |
| Genotype 3 (%) | 2.7 | 17.4 | 0.005 |
| Male sex (%) | 20.8 | 35.6 | 0.736 |

The values are reported as mean ± SD or percentages. ¹*P* values determined using independent-samples t-tests. BMI: Body mass index.

In the unadjusted regression analysis of the effect of the baseline demographic and clinical variables on treatment response, the ORs for HCV genotype 3 and age were significant (OR = 5.35; 95%CI: 1.48-19.3; *P* = 0.01 and OR = 0.959; 95%CI: 0.926-9.93; *P* = 0.019; respectively), suggesting positive effects of genotype 3 and relatively young age on response to treatment (Table 4). While the rate of hepatic steatosis as determined using abdominal ultrasound (16.5%) was not significant, the rate of hepatic steatosis as determined by liver biopsy (64%) tended to result in a better response (*P* = 0.085) (Table 4).

### Table 3 Unadjusted logistic regression analysis of the association between baseline metabolic components and antiviral treatment response (n = 115)

| Variables | Crude OR | 95%CI (*P* value) |
|-----------|----------|-------------------|
| BMI > 30 kg/m² | 0.825 | 0.303-2.243 (0.706) |
| IFG (> 100 mg/dL) | 0.609 | 0.266-1.393 (0.140) |
| T2DM (diagnosis, fasting blood glucose > 126 mg/dL, or use of anti-diabetic drugs) | 1.094 | 0.301-3.975 (0.892) |
| High blood pressure (> 16/10.66 kPa) | 0.713 | 0.269-1.889 (0.495) |
| High triglycerides | 1.075 | 0.338-2.978 (0.889) |
| High cholesterol and low HDL levels | 0.782 | 0.367-1.666 (0.523) |
| Presence of any metabolic syndrome components (high cholesterol levels, hyperlipidemia, high BP, or BMI > 30), without T2DM | 0.448 | 0.551-1.301 (0.847) |
| Metabolic syndrome | 0.597 | 0.141-2.520 (0.483) |

The non-responder group is the reference group. OR: Odds ratio; BMI: Body mass index; IFG: Impaired fasting glucose; T2DM: Type 2 diabetes mellitus; HDL: High-density lipoprotein cholesterol; BP: Blood pressure.

Univariable and multivariable logistic regression analyses of the effect of antiviral therapy response on the *de novo* impaired MS components resulted in significant
Our study, which aimed to examine the association between MS components and HCV infection based on treatment response and the influence of MS components on the success of antiviral therapy, did not detect any differences in most pre- or post-treatment MS component values between responders and non-responders to antiviral therapy. However, de novo IFG and T2DM occurred significantly more often in non-responders than in responders.

Our results regarding T2DM are consistent with those of other studies conducted with larger community cohorts. In a study conducted in Taiwan with a 7-year follow-up period, the cumulative incidence of T2DM was 14.3% in anti-HCV-positive patients and 8.6% in seronegative individuals (P < 0.0001). In another study conducted in Japan, 143 of 2842 HCV-positive patients treated with IFNα monotherapy or IFNα and ribavirin combination therapy developed T2DM during a mean observation period of 6.4 years, and only 26 of these patients with T2DM had SVR.

HCV infection causes insulin resistance in the very early stage hepatic lesions (fibrosis stage 0 or 1). The progression of fibrosis, primarily owing to insulin resistance, worsens insulin resistance, which may lead to T2DM in predisposed individuals. In addition to SVR, fibrosis stage is independently associated with T2DM in HCV-infected patients. Furthermore, a recent meta-analysis and systematic review included 11 studies, of which only five examined the influence of...
HCV eradication on the risk of de novo glucose abnormalities and insulin resistance. Of the 2 studies with long follow-up periods [19,26], one (8-year follow-up) failed to demonstrate reduced de novo T2DM in patients with SVR [19]. The other (follow-up of 5.7 ± 2 years) showed that SVR reduced de novo glucose abnormalities in patients with chronic HCV. However, patient ages were not reported [26]. In another study with a relatively short follow-up (24 mo), SVR in patients with chronic HCV who did not have T2DM (51.8 ± 12.2 years old) prevented the development of de novo insulin resistance [28]. A significant two-third reduction in T2DM development was reported in a large cohort of patients with HCV and SVR (51.8 ± 9 years old) after IFNα monotherapy or combination therapy with IFNα and ribavirin [22]. Thus, curing HCV infections decreases the incidence of T2DM or improves homeostatic model assessment insulin resistance (HOMA-IR) in most studies [22-33]. These effects might be specific to patients with particular genotypes, with a reduction in HOMA-IR in patients with HCV genotype 1 but not those with genotypes 2/3 [27]. Antiviral therapy might improve insulin resistance independent of virological outcomes although a greater reduction in HOMA was observed in the patients who achieved persistent HCV clearance. Antiviral therapy might also improve hepatic steatosis and fibrosis [29,34,35]. Thus, there might be an association between HCV and MS, and patients with HCV infection and MS have higher HOMA-IR values.

Several other components of MS, including waist circumference, BMI, and arterial hypertension, have been reported more frequently in non-responders to antiviral therapy [15]. The present study failed to demonstrate a significant relationship between baseline metabolic factors and treatment responses, potentially owing to the relatively young sample population. However, some metabolic factors (apart from T2DM) showed trends for differences based on the treatment response (e.g., de novo hypertriglyceridemia was 3.7 times more frequent in the responders than in the non-responders).

A bidirectional relationship between serum lipid levels and success of antiviral therapy for HCV has been reported [36]. Successful antiviral therapy might reverse the low LDL cholesterol, HDL cholesterol, and TG levels associated with HCV infection [7,12,13]. Low serum LDL levels in HCV infection result from the utilization of geranyl-geranyl phosphate, a product of the mevalonate pathway that is an early branch point of the cholesterol synthetic pathway, for HCV replication [1,7]. Higher baseline serum LDL cholesterol and lower serum TG levels were associated with higher rates of SVR [34], and lower serum LDL cholesterol levels correlated with low rates of SVR [33,35] in non-diabetic, non-cirrhotic patients infected with genotype 1 HCV. High serum LDL cholesterol levels...
might improve the rates of SVR by competing with binding to hepatocyte LDL receptors and subsequently reducing the infection of hepatocytes with HCV[4,11,34]. In contrast, HDL cholesterol enhances HCV infection by facilitating its entry into hepatocytes[21]. However, high baseline serum HDL cholesterol levels reportedly interfere with the early viral response, but not with SVR[3,4], while serum HDL cholesterol inversely correlates with the rate of SVR in men but not in women, resulting in a lack of an association between overall baseline HDL levels and SVR[11].

Hepatic steatosis might also attenuate the antiviral treatment response, a trend that was demonstrated in the present study based on steatosis identified via liver biopsy. The insulin resistance and hepatic steatosis present during HCV infection are genotype-specific. Lower HOMA values are reported in patients infected with genotype 3 than in those infected with genotype 1. Insulin resistance-associated steatosis, which is present in patients with HCV genotype 3, is caused mainly by viral inhibition of the enzyme microsomal triglyceride transfer protein (viral steatosis), which might resolve with successful antiviral therapy. With the other HCV genotypes, steatosis is due to insulin resistance, stimulation of fatty acid synthesis, and inhibition of mitochondrial β-oxidation (metabolic steatosis)[37-39]. Metabolic steatosis might be associated with a high BMI and central obesity, which are not usually improved by viral eradication. HCV 1 and 4 core proteins might cause insulin resistance by functionally inhibiting insulin signaling pathways via increased levels of pro-inflammatory cytokines including tumor necrosis factor (TNF) and suppressors of cytokine signaling (SOCS) proteins, which impair insulin signaling and activate sterol regulatory element binding proteins, resulting in increased hepatic lipid synthesis[37,39]. The increased levels of hepatic proinflammatory cytokines have additional effect of negative regulate IFNα transduction.

This might explain the molecular link between insulin resistance and the nonresponse to antiviral therapy[40]. Furthermore, steatosis has been demonstrated to decrease SVR in HCV genotype 1 but not in HCV genotype 3, although steatosis is a predictor of HCV infection relapse with genotype 3 HCV[16]. This effect of steatosis on SVR might be the result of its association with insulin resistance[40], which is caused by excretion of TNFα and SOCS protein from the increased trunk fat in HCV infection. The lower level of PPAR-alpha mRNA also mediates genotype 3 hepatic steatogenesis[7,8,39]. However, Peg-IFNα and ribavirin treatment response with HCV genotype 3 infection is better than with HCV genotype 1, despite more severe steatosis and lower cholesterol levels[10,37,40]. This might be related to the association between steatosis and higher BMI with genotypes 1 and 4[4,15].

It is noteworthy that, even in the era of direct acting antiviral (DAA; e.g., telaprevir and boceprevir)-based triple therapy, some baseline metabolic variables might affect SVR, albeit to a lesser degree than with IFN and ribavirin combination therapy[41]. However, insulin resistance does not predict SVR to telaprevir-based triple therapy or to the protease inhibitor danoprevir monotherapy[16,42], while low serum LDL levels might affect SVR in telaprevir-treated patients, and obesity impairs SVR in patients treated with boceprevir-based regimen[16,41]. An additional link between DAA and MS has been demonstrated with danoprevir monotherapy, an inhibitor of NS3/3A HCV serine protease, which might increase insulin sensitivity considerably, independent of its antiviral effect[5,36,42]. Furthermore, DAAAs are less effective against genotype 3 HCV infection, partly due to steatosis[43] and relapse after IFN-free therapy with the polymerase inhibitor sofosbuvir and ribavirin is associated with a low baseline LDL level.

This study has certain limitations. First, the study was retrospective, and some data were missing for some cases. Serum glucose levels were examined for diagnosis and monitoring glycemic control of T2DM and IGF. However, due to the retrospective nature of this manuscript, HbA1c and glycate albumin (GA) values were not available in most of the patients’ charts. Nevertheless, liver cirrhosis and INS alpha values may falsely decrease HbA1c owing to hemolysis. On the other hand, GA as a glycemic control marker in patients with chronic liver disease may be overestimated, due to prolonged albumin half-life.

Additionally, the small sample size resulted in a small number of responders with de novo T2DM and non-responders with de novo hypertriglyceridemia, which limited the ability to assess these data in the multivariable logistic regression analysis.

However, the strengths of the study include the relatively young age of the patients and the relatively long follow-up period for all MS components after antiviral treatment, which enabled us to observe the effect of SVR on the cumulative incidences of IFG and T2DM. MS, including insulin resistance, hyperglycemia, high BMI, and liver steatosis, might complicate the disease course of patients infected with HCV, by enhancing cirrhosis, HCC, and cardiovascular disease[29,43-47]. Thus, it is worthwhile to screen these patients for T2DM[46,47]. Furthermore, with T2DM in the presence of HCV, there are specific considerations for antidiabetic treatment. Insulin and sulfonylurea administration might increase the risk of HCC[45,46], while the insulin sensitizers metformin and pioglitazone might decrease the risk of HCC and steatosis. However, these agents are harmful and might cause lactic acidosis and hepatic toxicity, respectively, in patients with liver cirrhosis[45]. The new dipeptidyl peptidase-4 inhibitors appear promising[46,47,49].

In conclusion, the results presented here suggest that MS components did not have any significant effect on the response to antiviral therapy, although hepatic steatosis tended to impair the response to antiviral treatment.
There were no differences in the post-treatment changes in most MS components between responders and non-responders to antiviral therapy. However, the incidences of de novo T2DM and IFG were significantly higher in non-responders. Given the younger age of the patient population in the present study compared to previous similar studies, the findings might suggest a direct effect of HCV on the development of T2DM independent of fibrosis or cirrhosis. The higher serum TG levels after SVR exemplify the interaction between HCV infection and lipid metabolic pathways. Due to the increased risk of HCV infection with T2DM, it might be appropriate to screen HCV patients for T2DM and insulin resistance and to consider treatment of T2DM in the presence of HCV with new antidiabetic agents.

COMMENTS

Background
A bidirectional association exists between chronic hepatitis C virus (HCV) infection and some components of metabolic syndrome (MS).

Research frontiers
Most, but not all, previous studies showed an association between chronic HCV infection and MS components, including type 2 diabetes mellitus (T2DM), insulin resistance, elevated body mass index, and hepatic steatosis. Several host MS components might affect the disease course and sustained virological response (SVR) of HCV-infected patients treated with pegylated-interferon α (Peg-IFNα) and ribavirin. On the other hand, SVR can affect some MS components, mainly decreased insulin resistance (IR) and decreased de novo occurrence of T2DM.

Innovations and breakthroughs
This study, which included a younger patient cohort, was designed to assess associations between MS components and HCV infection, but it did not show increased prevalence of T2DM with HCV infection. However, after long term follow-up T2DM was more frequent in non-responders to treatment with Peg-IFNα and ribavirin.

Applications
Patients with HCV infection should be frequently monitored for T2DM and treated appropriately, considering the increased risk of cirrhosis and HCC in young patients with HCV-associated diabetes mellitus. The authors think that further studies are needed to evaluate the mutual association of MS components with direct acting antiviral (DAA) drug therapy in chronic HCV infection.

Terminology
MS components refer to the metabolic syndrome factors; IR refers to insulin resistance; SVR refers to sustained virological response, which means viral eradication and cure; DAA refers to direct acting antiviral agents.

Peer-review
This is a very interesting study which shows the association between metabolic syndrome mechanism and response to antiviral treatment for chronic HCV infection. Patients were followed up for about 4 years; unvariable and multivariable logistic regression analysis were applied. Data are well presented and discussed.

REFERENCES
1 Felmez DJ, Hafrissou ML, LeFebre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproprotein—impact for the viral life cycle and pathogenesis of liver disease. *Viruses* 2013; 5: 1292-1324 [PMID: 23698400 DOI: 10.3390/v5051292]
2 Pécheur EI. Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. *Scientifica* (Cairo) 2012; 2012: 709853 [PMID: 24278733 DOI: 10.6004/2012/709853]
3 Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. *PloS Pathog* 2007; 3: e108 [PMID: 17784784 DOI: 10.1371/journal.ppat.0030108]
4 Kawaguchi Y, Mizuta T. Interaction between hepatitis C virus and metabolic factors. *World J Gastroenterol* 2014; 20: 2888-2901 [PMID: 24659880 DOI: 10.3748/wjg.v20.i11.2888]
5 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. *Expert Opin Pharmacother* 2011; 12: 2215-2234 [PMID: 21883025 DOI: 10.1517/14656566.2011.597742]
6 Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. *Diabetes Care* 2006; 29: 1140-1149 [PMID: 16644655 DOI: 10.2337/dc05-1995]
7 Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. *World J Gastroenterol* 2006; 12: 6756-6765 [PMID: 17106922 DOI: 10.3748/wjg.v12.i42.6756]
8 Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. *World J Gastroenterol* 2014; 20: 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089]
9 Negro F. HCV infection and metabolic syndrome: which is the chicken and which is the egg? *Gastroenterology* 2012; 142: 1288-1292 [PMID: 22557345 DOI: 10.1053/j.gastro.2011.12.063]
10 Adinolfi LE, Restivo L, Marrone A. The predictive value of steatosis in hepatitis C virus infection. *Expert Rev Gastroenterol Hepatol* 2013; 7: 205-213 [PMID: 23445230 DOI: 10.1586/egh.13.7]
11 Ramcharran D, Wahed AS, Conjevaram HS, Evans RW, Wang T, Belle SH, Yee LJ. Associations between serum lipids and hepatitis C viral treatment efficacy. *Hepatology* 2010; 52: 854-863 [PMID: 20690192 DOI: 10.1002/hep.23796]
12 Fernández-Rodríguez CM, López-Serrano P, Alonso S, Gutiérrez ML, Lledó JL, Pérez-Calle JL, Temiño R, Cacho G, Nevado M, Martín AM, Benito J. Impact of liver steatosis on the antiviral treatment in chronic hepatitis C. *Liver Int* 2006; 24: 507-512 [PMID: 16889916 DOI: 10.1111/j.1365-2026.2006.03000.x]
13 Kou YH, Chuang TW, Hung CH, Chen CH, Wang JH, Hu TH, Lu SN, Lee CM. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. *J Forms Med Aids* 2011; 110: 363-371 [PMID: 21741004 DOI: 10.1016/S0929-6646(11)60054-5]
14 Soares M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. *Liver Int* 2006; 26: 1119-1125 [PMID: 17032413 DOI: 10.1111/j.1478-3231.2006.01347.x]
15 Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology* 2003; 38: 639-644 [PMID: 12939590 DOI: 10.1053/heap.2003.50350]
16 Cheng FK, Torres DM, Harrison SA. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? *J Viral Hepat* 2014; 21: 1-8 [PMID: 23429852 DOI: 10.1111/jvhe.12172]
17 Tarantino G, Conca P, Sorrentino P, Acri M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. *J Gastroenterol Hepatol* 2006; 21: 1266-1268 [PMID: 16872307 DOI: 10.1111/j.1440-1746.2006.04394.x]
18 Cheng YL, Wang YC, Lan KH, Hsu HC, Huang YH, Su CW, Lin HC, Lee FY, Wu JCC, Lee SD. Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. *Ann Hepatol* 2015; 14: 181-189 [PMID: 25671827]
19 Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML,
Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Ruzzetto M, Saracco G. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008; 103: 2481-2487 [PMID: 18702647 DOI: 10.1111/j.1572-0241.2008.02002.x]

20 Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24: e13-e18 [PMID: 14766739 DOI: 10.1161/01.ATV.0000124575.75526.CE]

21 Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007; 166: 196-203 [PMID: 17496314 DOI: 10.1093/aje/kwm061]

22 Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaaka T, Hirokawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-744 [PMID: 19127513 DOI: 10.1002/hep.22703]

23 Thompson AJ, Patel K, Chung WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Filiash R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012; 61: 128-134 [PMID: 21873466 DOI: 10.1136/gut.2010.236158]

24 Romero-Gómez M, Fernández-Rodriguez CM, Andrade RJ, Basaranoglu G. Pathophysiology of insulin resistance during antiviral therapy for chronic hepatitis C. Gastroenterol Hepatol (N Y) 2012; 8: 305-312 [PMID: 22933860]

25 Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85 [PMID: 12829998 DOI: 10.1053/jhep.2003.50267]

26 Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, Lin YZ, Chen SC, Wang LY, Chuang WL, Yu ML, Tang HD. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2015; 30: 879-884 [PMID: 23808794 DOI: 10.1111/j.1440-1746.2013.12313]

27 Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009; 15: 1537-1547 [PMID: 19340895 DOI: 10.3748/wjg.v15.i15.1537]

28 Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol (N Y) 2012; 8: 305-312 [PMID: 22933860]

29 Ungasiens E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 2012; 56 Suppl 1: S56-S65 [PMID: 22300466 DOI: 10.1016/S0168-8278(12)60007-5]

30 Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 2011; 17: 4505-4562 [PMID: 22039318 DOI: 10.3748/wjg.v17.i36.4055]

31 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19: 6947-6956 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947]

32 Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H, Vidaud M, Seiwert S, Bradford B, Zeuzem S, Marcellin P. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010; 59: 1694-1698 [PMID: 20861007 DOI: 10.1136/gut.2010.219089]

33 Lim T. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? Hepat Med 2014; 6: 113-118 [PMID: 25506251 DOI: 10.2147/HMER.S60083]

34 Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61: S69-S78 [PMID: 25443347 DOI: 10.1016/j.jhep.2014.08.003]

35 Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. J World J Gastroenterol 2010; 16: 1943-1952 [PMID: 20419831 DOI: 10.3748/wjg.v16.i16.1943]

36 Hammerstad SS, Brock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) 2015; 6: 134 [PMID: 26441826 DOI: 10.3389/fendo.2015.00134]

37 García-Compeán D, González-González JA, Lalvalle-González FJ, González-Moreno EL, Villarreal-Pérez IZ, Maldonado-Garza HJ. Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Dig Dis Sci 2016; 61: 371-380 [PMID: 26462490 DOI: 10.1007/s00410-015-3906-2]
Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata M. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. *Liver Int* 2010; 30: 479-486

Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. *World J Gastroenterol* 2013; 19: 2298-2306 [PMID: 23613622 DOI: 10.3748/wjg.v19.i15.2298]
